Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10833047 | Molecular Genetics and Metabolism | 2015 | 11 Pages |
Abstract
Leukodystrophies are inherited disorders whose primary pathophysiology consists of abnormal deposition or progressive disruption of brain myelin. Leukodystrophy patients manifest many of the same symptoms and medical complications despite the wide spectrum of genetic origins. Although no definitive cures exist, all of these conditions are treatable. This report provides the first expert consensus on the recognition and treatment of medical and psychosocial complications associated with leukodystrophies. We include a discussion of serious and potentially preventable medical complications and propose several preventive care strategies. We also outline the need for future research to prioritize clinical needs and subsequently develop, validate, and optimize specific care strategies.
Keywords
ADLDX-ALDX-linked adrenoleukodystrophyAGSMLDVWMCTXAxDUTIsConsensusVanishing white matter diseaseCarealexander diseaseComparative effectiveness researchcomputed tomographyTherapyCerebrotendinous xanthomatosisCerUrinary tract infectionsOutcomesLeukodystrophyMetachromatic leukodystrophyPol IIIpolymerase IIIPreventionGlia
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Keith Van Haren, Joshua L. Bonkowsky, Genevieve Bernard, Jennifer L. Murphy, Amy Pizzino, Guy Helman, Dean Suhr, Jacque Waggoner, Don Hobson, Adeline Vanderver, Marc C. Patterson, on behalf of the GLIA Consortium on behalf of the GLIA Consortium,